X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
ECT-001 Cell Therapy combines proprietary molecule UM171, and an optimized culture system. ECT‑001 Cell Therapy has been evaluated in over 100 adult and pediatric patients with severe blood disorders in several clinical trials in the United States and Canada.
Lead Product(s): UM171-expanded Cord Blood Cell Therapy
Therapeutic Area: Oncology Product Name: ECT-001
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 15, 2022
Details:
ECT-001 Cell Therapy combines proprietary molecule UM171, and an optimized culture system. ECT‑001 Cell Therapy has now been evaluated in 100 adult and pediatric patients with severe blood disorders in several clinical trials in the United States and Canada.
Lead Product(s): UM171-expanded Cord Blood Cell Therapy
Therapeutic Area: Oncology Product Name: ECT-001
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 08, 2022
Details:
ECT-001-CB (UM171-Expanded Cord Blood Transplant), a cell therapy under clinical development, to treat patients with severe leukemia. By a 10-fold increase of CB accessibility, ECT-001-CB allowed access to smaller, better HLA matched CBs.
Lead Product(s): ECT-001-CB,Fludarabine Phosphate,Cyclophosphamide
Therapeutic Area: Oncology Product Name: ECT-001-CB
Highest Development Status: Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 15, 2022
Details:
UM171 selectively expands EPCR+ cord blood HSCs with sustained short- and long-term repopulation potential, and mobilized peripheral blood HSCs following lentiviral transduction.
Lead Product(s): UM171-based PSC-derived Cells
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Astellas Pharma
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement July 13, 2021
Details:
IRICoR's investment enabled ExCellThera to secure the co-funding required in connection with the grant awarded to it from the California Institute for Regenerative Medicine for a Phase 1 clinical trial using its ECT-001, for the treatment of severe sickle cell disease.
Lead Product(s): ECT-001
Therapeutic Area: Genetic Disease Product Name: ECT-001
Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: IRICoR
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Funding August 07, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
